Actinium Pharmaceuticals, Inc.: Business Overview, Financials & Competitive Analysis
Actinium Pharmaceuticals, Inc. scores 5/10 on the AskCyborg Cyborg Score (Mixed). Early-stage biotech with novel technology but significant execution risk dependent on clinical trial success and regulatory approval. As a mid-stage biopharmaceutical company, Actinium faces typical sector risks including clinical trial uncertainty, regulatory dependencies, and capital intensity, balanced against its differentiated radiopharmaceutical technology platform and focused oncology strategy.
What is Actinium Pharmaceuticals, Inc.'s industry? Actinium Pharmaceuticals, Inc. (actiniumpharma.com) operates in Biopharmaceuticals/Radiopharmaceuticals/Oncology Therapeutics. AskCyborg classifies Actinium Pharmaceuticals, Inc. under Biopharmaceuticals/Radiopharmaceuticals/Oncology Therapeutics in its company registry.
Actinium Pharmaceuticals is a biopharmaceutical company focused on developing targeted therapeutics for oncology and hematologic malignancies. The company specializes in radioimmunotherapy and is advancing a pipeline ...
Cyborg Score thesis
Early-stage biotech with novel technology but significant execution risk dependent on clinical trial success and regulatory...
Read the full analyst-debate transcript →Get the Latest Actinium Pharmaceuticals, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeActinium Pharmaceuticals, Inc. Overview
Pro stress-test →Actinium Pharmaceuticals is a biopharmaceutical company focused on developing targeted therapeutics for oncology and hematologic malignancies. The company specializes in radioimmunotherapy and is advancing a pipeline of proprietary drugs designed to deliver targeted alpha-particle and beta-particle radiation directly to cancer cells.
Strategic Profile
Pro stress-test →Actinium differentiates itself through its proprietary radiopharmaceutical technology platform that combines antibodies with radioactive isotopes to create precision oncology solutions. The company's strategy centers on advancing lead clinical candidates toward regulatory milestones while maintaining focus on rare and difficult-to-treat malignancies where it can establish competitive advantages.
Competitive Landscape
Pro stress-test →Actinium competes in the radiopharmaceutical and oncology therapeutics space against larger biopharmaceuticals developing similar targeted therapies and immunotherapies. Major competitive areas include companies working on alpha-therapy, radioimmunotherapy, and precision oncology approaches.
Industry Context
Actinium Pharmaceuticals, Inc. operates in Biopharmaceuticals/Radiopharmaceuticals/Oncology Therapeutics.
Key facts
Founded: 2000 · Headquarters: New York, US